Tags

Type your tag names separated by a space and hit enter

Management of androgenetic alopecia.
J Eur Acad Dermatol Venereol. 1999 May; 12(3):205-14.JE

Abstract

BACKGROUND

Androgenetic alopecia (AGA) is the most frequent cause of hair loss affecting up to 50% of men and 40% of women by the age of 50.

METHODS

This paper outlines the current status of diagnosis and offers guidelines for optimal management of AGA in both men and women.

RESULTS

The diagnosis of AGA can usually be confirmed by medical history and physical examination alone. A trichogram can be useful to assess the progression of the hair loss. A scalp biospy is diagnostic but usually not required. In women with signs of hyperandrogenism, investigation for ovarian (polycystic ovarian disease) or adrenal (late-onset congenital adrenal hyperplasia) disorders is required. Mild to moderate AGA in men can be treated with oral finasteride or topical minoxidil. Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66% of patients treated for 2 years. The drug is effective for both frontal and vertex hair thinning. Medical treatment with finasteride or minoxidil should be continued indefinitely since interruption of therapy leads to hair loss with return to pretreatment status. Mild to moderate AGA in women can be treated with oral antiandrogens (cyproterone acetate, spironolactone) and/or topical minoxidil with good results in many cases. Hair systems and surgery may be considered for selected cases of severe AGA both in men and in women.

CONCLUSIONS

Patients with AGA should be informed about the pathogenesis of the condition. If used correctly, available medical treatments arrest progression of the disease and reverse miniaturization in most patients with mild to moderate AGA.

Authors+Show Affiliations

Department of Dermatology, University of Bologna, Italy. tosti@almadns.unibo.itNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

10461639

Citation

Tosti, A, et al. "Management of Androgenetic Alopecia." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 12, no. 3, 1999, pp. 205-14.
Tosti A, Camacho-Martinez F, Dawber R. Management of androgenetic alopecia. J Eur Acad Dermatol Venereol. 1999;12(3):205-14.
Tosti, A., Camacho-Martinez, F., & Dawber, R. (1999). Management of androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology : JEADV, 12(3), 205-14.
Tosti A, Camacho-Martinez F, Dawber R. Management of Androgenetic Alopecia. J Eur Acad Dermatol Venereol. 1999;12(3):205-14. PubMed PMID: 10461639.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Management of androgenetic alopecia. AU - Tosti,A, AU - Camacho-Martinez,F, AU - Dawber,R, PY - 1999/8/26/pubmed PY - 1999/8/26/medline PY - 1999/8/26/entrez SP - 205 EP - 14 JF - Journal of the European Academy of Dermatology and Venereology : JEADV JO - J Eur Acad Dermatol Venereol VL - 12 IS - 3 N2 - BACKGROUND: Androgenetic alopecia (AGA) is the most frequent cause of hair loss affecting up to 50% of men and 40% of women by the age of 50. METHODS: This paper outlines the current status of diagnosis and offers guidelines for optimal management of AGA in both men and women. RESULTS: The diagnosis of AGA can usually be confirmed by medical history and physical examination alone. A trichogram can be useful to assess the progression of the hair loss. A scalp biospy is diagnostic but usually not required. In women with signs of hyperandrogenism, investigation for ovarian (polycystic ovarian disease) or adrenal (late-onset congenital adrenal hyperplasia) disorders is required. Mild to moderate AGA in men can be treated with oral finasteride or topical minoxidil. Oral finasteride at the dosage of 1 mg/day produced clinical improvement in up to 66% of patients treated for 2 years. The drug is effective for both frontal and vertex hair thinning. Medical treatment with finasteride or minoxidil should be continued indefinitely since interruption of therapy leads to hair loss with return to pretreatment status. Mild to moderate AGA in women can be treated with oral antiandrogens (cyproterone acetate, spironolactone) and/or topical minoxidil with good results in many cases. Hair systems and surgery may be considered for selected cases of severe AGA both in men and in women. CONCLUSIONS: Patients with AGA should be informed about the pathogenesis of the condition. If used correctly, available medical treatments arrest progression of the disease and reverse miniaturization in most patients with mild to moderate AGA. SN - 0926-9959 UR - https://www.unboundmedicine.com/medline/citation/10461639/Management_of_androgenetic_alopecia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0926995999000409 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.